McMillan Shakespeare Ltd (ASX: MMS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
McMillan Shakespeare Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$765.30 million
P/E Ratio
11.71
Dividend Yield
6.59%
Shares Outstanding
77.38 million
Earnings per share
0.844
Dividend per share
0.68
Year To Date Return
-15.40%
Earnings Yield
8.54%
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
McMillan Shakespeare Ltd (ASX: MMS)
Latest News
Share Fallers
McMillan Shakespeare (ASX:MMS) share price plummets 9% despite 2500% rise in NPAT
Share Market News
Why the McMillan Shakespeare (ASX:MMS) share price has slipped today
⏸️ ASX Shares
3 top ASX shares to buy according to WAM
Cheap Shares
3 forgotten ASX stocks left behind in the car sales recovery
Share Market News
McMillan (ASX:MMS) share price on watch today. Here’s why
Cheap Shares
Top brokers just upgraded the ResMed (ASX:RMD) share price and this other ASX stock
Share Market News
McMillan (ASX:MMS) share price edges up on AGM
Share Market News
ASX 200 jumps 2.6%, big 4 banks surge
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 10 Mar 2022 | $0.3400 | 100.00% | Interim | 25 Mar 2022 |
| 09 Sep 2021 | $0.3110 | 100.00% | Final | 24 Sep 2021 |
| 11 Mar 2021 | $0.3020 | 100.00% | Interim | 26 Mar 2021 |
| 05 Mar 2020 | $0.3400 | 100.00% | Interim | 20 Mar 2020 |
| 28 Aug 2019 | $0.4000 | 100.00% | Final | 11 Sep 2019 |
| 07 Mar 2019 | $0.3400 | 100.00% | Interim | 22 Mar 2019 |
| 13 Sep 2018 | $0.4000 | 100.00% | Final | 28 Sep 2018 |
| 15 Mar 2018 | $0.3300 | 100.00% | Interim | 29 Mar 2018 |
| 28 Sep 2017 | $0.3500 | 100.00% | Final | 13 Oct 2017 |
| 30 Mar 2017 | $0.3100 | 100.00% | Interim | 13 Apr 2017 |
| 29 Sep 2016 | $0.3400 | 100.00% | Final | 14 Oct 2016 |
| 31 Mar 2016 | $0.2900 | 100.00% | Interim | 15 Apr 2016 |
| 29 Sep 2015 | $0.2700 | 100.00% | 16 Oct 2015 | |
| 30 Mar 2015 | $0.2500 | 100.00% | 17 Apr 2015 | |
| 29 Sep 2014 | $0.3100 | 100.00% | 15 Oct 2014 | |
| 16 Sep 2010 | $0.1400 | 100.00% | Final | 15 Oct 2010 |
MMS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About McMillan Shakespeare Ltd
McMillan Shakespeare Limited (ASX: MMS) is a market leader in salary packaging, novated leasing, and fleet and asset management services. McMillan provides services to major employers across Australia, New Zealand and the United Kingdom through brands including Maxxia, RemServ, Interleasing and Holden Leasing.
Clients include state and federal governments, hospitals, not-for-profit organisations and private corporations.
From its origins in 1988 when McMillan first pioneered Australia’s salary packaging industry, the company has grown into a global organisation and top 200 ASX-listed company. With more than 1,200 staff, offices and representatives in every Australian state and territory, as well as Auckland and London, McMillan manages more than 290,000 employee benefit programs and more than 70,000 vehicles.
The McMillan share price has been impacted in FY20 as the COVID-19 pandemic sent a wrecking ball through Australia’s workforce. However, the professional services firm is gaining traction with its rapid digital program expansion to service customers remotely.
MMS Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 05 Jul 2022 | $9.88 | $-0.17 | -1.69% | 138,180 | $10.09 | $10.18 | $9.80 |
| 04 Jul 2022 | $10.05 | $0.31 | 3.18% | 121,021 | $9.84 | $10.33 | $9.84 |
| 01 Jul 2022 | $9.74 | $0.00 | 0.00% | 69,964 | $9.88 | $9.94 | $9.74 |
| 30 Jun 2022 | $9.74 | $0.10 | 1.04% | 218,279 | $9.64 | $9.84 | $9.63 |
| 29 Jun 2022 | $9.64 | $-0.10 | -1.03% | 172,407 | $9.64 | $9.69 | $9.48 |
| 28 Jun 2022 | $9.74 | $-0.05 | -0.51% | 126,494 | $9.73 | $9.91 | $9.66 |
| 27 Jun 2022 | $9.79 | $0.19 | 1.98% | 191,813 | $9.76 | $9.90 | $9.50 |
| 24 Jun 2022 | $9.60 | $0.30 | 3.23% | 201,493 | $9.31 | $10.04 | $9.28 |
| 23 Jun 2022 | $9.30 | $0.23 | 2.54% | 639,837 | $9.18 | $9.50 | $9.09 |
| 22 Jun 2022 | $9.07 | $-0.32 | -3.41% | 147,865 | $9.43 | $9.59 | $8.94 |
| 21 Jun 2022 | $9.39 | $0.38 | 4.22% | 200,212 | $9.10 | $9.39 | $9.07 |
| 20 Jun 2022 | $9.01 | $-0.23 | -2.49% | 126,150 | $9.30 | $9.32 | $8.89 |
| 17 Jun 2022 | $9.24 | $-0.15 | -1.60% | 308,624 | $9.32 | $9.39 | $9.03 |
| 16 Jun 2022 | $9.39 | $-0.35 | -3.59% | 216,303 | $9.75 | $9.82 | $9.35 |
| 15 Jun 2022 | $9.74 | $-0.12 | -1.22% | 180,633 | $9.95 | $9.95 | $9.68 |
| 14 Jun 2022 | $9.86 | $-0.39 | -3.80% | 329,352 | $10.05 | $10.15 | $9.67 |
| 10 Jun 2022 | $10.25 | $-0.01 | -0.10% | 178,173 | $10.38 | $10.38 | $10.02 |
| 09 Jun 2022 | $10.26 | $-0.31 | -2.93% | 295,727 | $10.57 | $10.57 | $10.11 |
| 08 Jun 2022 | $10.57 | $-0.45 | -4.08% | 126,334 | $11.00 | $11.05 | $10.45 |
| 07 Jun 2022 | $11.02 | $-0.39 | -3.42% | 96,123 | $11.47 | $11.47 | $10.96 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 30 Nov 2021 | Michael (Mike) Salisbury | Issued | 71 | $898,072 |
Issue of securities. As per announcement on 01/12/2021
203,165 - Performance Rights & Indeterminate Rights |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Timothy Michael Poole | Non-Executive Director | Dec 2013 |
Mr Poole is currently Chair of Aurizon Holdings Limited and a Non-Executive Director of Reece Limited. Mr Poole was previously an executive of the unlisted infrastructure and private equity manager, Hastings Funds Management (1995 to 2007), including being the Managing Director from 2005. He was formerly the Non-Executive Chair of Lifestyle Communities Limited. He is member of people, culture, risk & compliance committee.
|
| Mr Bruce John Akhurst | Non-Executive Director | Apr 2021 |
Mr Akhurst is currently Non-Executive Director, Chair of the Risk and Compliance Committee and a member of the People and Remuneration Committee and Technology Committee at Tabcorp Holdings Limited. Mr Akhurst is also Chair of the Peter McCallum Cancer Foundation and Council Member of RMIT University chairing the Technology and Infrastructure Committee. He was previously Non-Executive Director and a member of the People, Culture and Remuneration Committee of Vocus Group Limited, CEO of Sensis, Group MD and General Counsel of Telstra and a Partner of Mallesons Stephen Jaques. He is Member of risk & Compliance committee and chairperson of people and culture committee.
|
| Mr John G Bennetts | Non-Executive Director | Dec 2003 |
Mr Bennetts is an experienced investor and has been the founder and director of a number of successful Australian companies. He owns businesses in varied industries including technology and finance. He is a Non-Executive Director of Sacred Heart Mission. He was a founder of Cellestis Limited and private equity investment firm, Mooroolbark Investments Pty Limited (M-Group). He has also provided corporate advisory services to a range of companies in Australia and Asia. Prior to the establishment of M-Group, he was a senior executive of pioneering Australian multinational IT company, Datacraft Limited and also practised as a commercial lawyer. He is member of risk & compliance committee.
|
| Mr Ross Chessari | Non-Executive Director | Dec 2003 |
Mr Chessari is a founder and director of the investment manager, SciVentures Investments Pty Limited (SciVentures). Prior to founding SciVentures, Mr Chessari was the Managing Director of ANZ Asset Management and the General Manager of ANZ Trustees.
|
| Ms Helen Kurincic | Non-Executive DirectorNon-Executive Chairman | Sep 2018 |
Ms Kurincic is Non-Executive Chair of Integral Diagnostics Limited, Non-Executive Director of Estia Health Limited, HBF Health Limited and the Victorian Clinical Genetics Service. Formerly, Ms Kurincic was the Chief Operating Officer and Director of Genesis Care from its earliest inception, creating and developing the first and largest radiation oncology and cardiology business across Australia. She has also formerly held Board roles across the publicly listed, private, not-for-profit and government sectors as well as being the former CEO of Benetas and Heart Care Victoria. She is member of people, culture, risk & compliance committee.
|
| Mr Robert (Rob) De Luca | Chief Executive OfficerManaging Director | May 2022 |
Mr De Luca is a CEO with over 20 years' experience in banking, financial services, wealth management, and disability. Over that period, he has led and grown organizations through periods of technological, economic and regulatory change. Mr De Luca was formerly CEO of Zenitas Healthcare, CEO of the National Disability Insurance Agency and Managing Director of Bankwest. Prior to that he was at CBA in roles including Executive General Manager Retail & Business Banking, Executive General Manager Corporate Financial Services, CEO ASB Group Investments (NZ), Executive General Manager Wealth Management and Executive Manager E-Commerce Strategy & Ventures. He started his career as a Credit Analyst at NAB.
|
| Ms Kathryn Maree Parsons | Non-Executive Director | May 2020 |
Ms Parsons is a former audit partner at Ernst & Young where she spent time as a partner in the firm's US, UK and Australian practices. In addition to her audit client responsibilities she was part of the firm's Oceania Assurance Leadership team as the Professional Practice Director with responsibility for assurance quality and risk management in the region. She is member of people and culture committee and chairperson of risk & compliance committee.
|
| Mr Ashley Conn | Chief Financial OfficerCompany Secretary | Oct 2020 |
-
|
| Ashley Conn | Chief Financial OfficerCompany Secretary |
-
|
|
| G Kruyt | Chief Operating Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Aust) Ltd | 28,227,083 | 36.48% |
| J P Morgan Nominees Australia Pty Limited | 9,859,180 | 12.74% |
| Citicorp Nominees Limited | 7,633,731 | 9.87% |
| Chessari Holdings Pty Limited | 6,050,941 | 7.82% |
| Asia Pac Technology Pty Ltd | 3,068,025 | 3.96% |
| CS Third Nominees Pty Limited <Hsbc Cust Nom Au Ltd 13 A/C> | 2,457,774 | 3.18% |
| UBS Nominees Pty Ltd | 2,132,982 | 2.76% |
| National Nominees Limited | 1,943,961 | 2.51% |
| Ann Leslie Ryan | 1,008,418 | 1.30% |
| BNP Paribas Noms Pty Ltd <Drp> | 999,993 | 1.29% |
| Milton Corporate Limited | 803,532 | 1.04% |
| BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 723,575 | 0.94% |
| MOHL Invest Pty Ltd <MOHL Super Fund A/C> | 590,000 | 0.76% |
| Afico Pty Ltd | 495,625 | 0.64% |
| NWC Group Pty Ltd | 437,781 | 0.57% |
| Mr Kenneth Joseph Hall <Hall Park A/C) | 250,000 | 0.32% |
| BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> | 190,375 | 0.25% |
| HSBC Custody Nominees (Australia) Limited <NT Comnwlth Super Corp A/C> | 134,341 | 0.17% |
| BNP Paribas Nominees Pty Ltd <Ioof Instmt Mgt Ltd Drp> | 131,169 | 0.17% |
| MOD Enterprises Pty Ltd | 129,619 | 0.17% |